title: Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species.
abstract: Mycobacterium tuberculosis is a global public health concern, particularly with the emergence of drug-resistant strains. Immediate identification of drug-resistant strains is crucial to administering appropriate treatment before the bacteria are allowed to spread. However, developing countries, which are most affected by drug resistance, are struggling to combat the disease without the facilities or funds for expensive diagnostics. Recent studies have emphasized the suitability of isothermal microcalorimetry (IMC) for the rapid detection of mycobacteria. In this study, we investigate its suitability for rapid and reliable M. tuberculosis drug susceptibility testing. Specifically, IMC was used to determine the MICs of three drugs, namely, isoniazid, ethambutol, and moxifloxacin, against three mycobacteria, namely, Mycobacterium smegmatis, Mycobacterium avium, and Mycobacterium tuberculosis. The Richards growth model was used to calculate growth parameters, namely, the maximum bacterial growth rate and the lag phase duration from integrated heat flow-versus-time results. For example, MICs of isoniazid, ethambutol, and moxifloxacin were determined to be 1.00, 8.00, and 0.25 μg/ml, respectively. IMC, as described here, could be used not just in industrialized countries but also in developing countries because inexpensive and sensitive microcalorimeters are now available.
authors.affiliation: Laboratory of Biomechanics and Biocalorimetry, LOB2, c/o Biozentrum/Pharmazentrum, University of Basel, Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Howell
authors.forename: D
authors.initials: D
authors.lastname: Wirz
authors.forename: A U
authors.initials: AU
authors.lastname: Daniels
authors.forename: O
authors.initials: O
authors.lastname: Braissant
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology; D001372:Aza Compounds / Q000494:pharmacology*; D002151:Calorimetry / Q000379:methods; D004977:Ethambutol / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods*; D000077266:Moxifloxacin; D009162:Mycobacterium avium / Q000187:drug effects*; D020102:Mycobacterium smegmatis / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D004977:Ethambutol; D000077266:Moxifloxacin; D007538:Isoniazid
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4163-70
references.pmid: 15504836
references.citation: J Clin Microbiol. 2008 Jun;46(6):2083-7
references.pmid: 18417657
references.citation: J Clin Microbiol. 2002 May;40(5):1873-4
references.pmid: 11980982
references.citation: FEMS Microbiol Lett. 2010 Feb;303(1):1-8
references.pmid: 19895644
references.citation: Rev Infect Dis. 1987 Mar-Apr;9(2):275-94
references.pmid: 3296098
references.citation: Int J Antimicrob Agents. 2005 Jul;26(1):28-32
references.pmid: 15955675
references.citation: Int J Antimicrob Agents. 2002 Dec;20(6):464-7
references.pmid: 12458143
references.citation: Diagn Microbiol Infect Dis. 2007 Mar;57(3):283-7
references.pmid: 17338942
references.citation: J Clin Microbiol. 1998 May;36(5):1214-9
references.pmid: 9574679
references.citation: Antimicrob Agents Chemother. 1982 Jul;22(1):148-50
references.pmid: 7125626
references.citation: J Biotechnol. 2006 Apr 20;122(4):431-42
references.pmid: 16309773
references.citation: Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9
references.pmid: 9687408
references.citation: J Appl Microbiol. 2011 Oct;111(4):1016-24
references.pmid: 21797951
references.citation: APMIS. 2006 May;114(5):319-28
references.pmid: 16725007
references.citation: Antimicrob Agents Chemother. 2003 Nov;47(11):3616-9
references.pmid: 14576129
references.citation: Appl Environ Microbiol. 1990 Jun;56(6):1875-81
references.pmid: 16348228
references.citation: Diagn Microbiol Infect Dis. 2005 Oct;53(2):121-4
references.pmid: 16168616
references.citation: J Clin Microbiol. 2002 Feb;40(2):553-5
references.pmid: 11825971
references.citation: Int J Tuberc Lung Dis. 2010 Feb;14(2):131-40
references.pmid: 20074402
references.citation: Clin Microbiol Rev. 1992 Jan;5(1):1-25
references.pmid: 1735092
references.citation: Scand J Infect Dis. 2006;38(4):246-55
references.pmid: 16709525
references.citation: Sensors (Basel). 2010;10(10):9369-83
references.pmid: 22163413
references.citation: Antimicrob Agents Chemother. 2006 Jan;50(1):250-5
references.pmid: 16377694
references.citation: Antimicrob Agents Chemother. 2001 Jun;45(6):1934-6
references.pmid: 11353658
references.citation: Eur Respir J. 2005 Mar;25(3):564-9
references.pmid: 15738303
references.citation: Res Microbiol. 1992 Sep;143(7):721-30
references.pmid: 1488556
references.citation: Clin Microbiol Rev. 2011 Apr;24(2):314-50
references.pmid: 21482728
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3127-34
references.pmid: 18559650